Checkpoint Therapeutics (CKPT) News Today $3.75 +0.38 (+11.28%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III Sells 220,230 SharesDecember 21 at 7:24 AM | insidertrades.comJames F. Oliviero III Sells 220,230 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) StockCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CEO James F. Oliviero III sold 220,230 shares of the business's stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $3.38, for a total transaction of $744,377.40. Following the completion of the transaction, the chief executive officer now owns 3,194,583 shares of the company's stock, valued at approximately $10,797,690.54. This trade represents a 6.45 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.December 20 at 10:29 PM | marketbeat.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells 268,432 SharesCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CFO William Garrett Gray sold 268,432 shares of the business's stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $4.01, for a total value of $1,076,412.32. Following the completion of the transaction, the chief financial officer now directly owns 1,032,754 shares of the company's stock, valued at $4,141,343.54. The trade was a 20.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.December 20 at 10:29 PM | marketbeat.com**Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT for Treatment of Advanced Cutaneous Squamous Cell Carcinoma**December 19 at 4:17 AM | americanbankingnews.comCheckpoint Therapeutics: Updating My Strategy After Unloxcyt's ApprovalDecember 18 at 2:04 PM | seekingalpha.comLake Street Capital Increases Checkpoint Therapeutics (NASDAQ:CKPT) Price Target to $7.00December 18 at 1:55 AM | americanbankingnews.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Up 9.0% in NovemberCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the target of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 6,570,000 shares, a growth of 9.0% from the November 15th total of 6,030,000 shares. Currently, 16.2% of the shares of the company are sold short. Based on an average trading volume of 807,000 shares, the short-interest ratio is currently 8.1 days.December 16, 2024 | marketbeat.comCheckpoint Therapeutics Upgraded to Buy Following FDA Approval and Increased Price TargetDecember 16, 2024 | markets.businessinsider.comCheckpoint Therapeutics Sees Unusually High Options Volume (NASDAQ:CKPT)Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the recipient of unusually large options trading on Monday. Stock traders bought 7,866 call options on the company. This represents an increase of approximately 1,998% compared to the typical daily volume of 375 call options.December 16, 2024 | marketbeat.comLake Street Capital Forecasts Strong Price Appreciation for Checkpoint Therapeutics (NASDAQ:CKPT) StockLake Street Capital increased their price target on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a "buy" rating in a research report on Monday.December 16, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Checkpoint Therapeutics (NASDAQ:CKPT)HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Checkpoint Therapeutics in a research report on Monday.December 16, 2024 | marketbeat.comCheckpoint Therapeutics Gets Its First FDA ApprovalDecember 15, 2024 | marketwatch.comCheckpoint Therapeutics, Inc: Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (cosibelimab-ipdl)December 14, 2024 | finanznachrichten.deCheckpoint Therapeutics Announces FDA Approval of UNLOXCYT(TM) (cosibelimab-ipdl)December 14, 2024 | stockhouse.comCheckpoint Therapeutics' Shares Rise After Securing First FDA ApprovalDecember 14, 2024 | marketwatch.comCheckpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)December 14, 2024 | markets.businessinsider.comUS FDA approves Checkpoint's skin cancer drugDecember 14, 2024 | reuters.comCheckpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)December 13, 2024 | globenewswire.comBuy Rating for Checkpoint Therapeutics: Anticipated Approval of Cosibelimab and Strategic Growth OpportunitiesDecember 7, 2024 | markets.businessinsider.comFY2024 Earnings Forecast for CKPT Issued By HC WainwrightCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Free Report) - Equities research analysts at HC Wainwright cut their FY2024 earnings per share estimates for shares of Checkpoint Therapeutics in a research note issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that tNovember 18, 2024 | marketbeat.comCheckpoint Therapeutics Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.29 loss in 3Q 2023)November 16, 2024 | uk.finance.yahoo.comCheckpoint Therapeutics, Inc: Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate UpdatesNovember 14, 2024 | finanznachrichten.deOptimistic Buy Rating for Checkpoint Therapeutics Driven by Strong Financial Position and Strategic CollaborationsNovember 14, 2024 | markets.businessinsider.comCheckpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA DateNovember 14, 2024 | seekingalpha.comWest Virginia State Police to hold DUI Checkpoint in Mercer CountyNovember 14, 2024 | msn.comCheckpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate UpdatesNovember 12, 2024 | globenewswire.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) Sees Large Increase in Short InterestCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the recipient of a large growth in short interest in the month of October. As of October 15th, there was short interest totalling 4,610,000 shares, a growth of 5.3% from the September 30th total of 4,380,000 shares. Based on an average daily trading volume, of 459,900 shares, the days-to-cover ratio is presently 10.0 days. Approximately 12.3% of the company's shares are sold short.October 31, 2024 | marketbeat.comOvercoming Resistance to Checkpoint Inhibitor Cancer TherapyOctober 25, 2024 | forbes.comCheckpoint Therapeutics (NASDAQ:CKPT) Stock, Short Interest ReportOctober 8, 2024 | benzinga.comBodycam Footage Shows Influencer Therapist's 2023 DUI Arrest At NJ Town's Sobriety CheckpointOctober 4, 2024 | msn.comMetabolic reprogramming of T cells may enhance checkpoint inhibitor therapySeptember 26, 2024 | msn.comBuy Rating Justified by Promising Efficacy of Checkpoint’s Cosibelimab in Clinical TrialsSeptember 17, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Checkpoint Therapeutics (NASDAQ:CKPT)HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Checkpoint Therapeutics in a research report on Monday.September 16, 2024 | marketbeat.comCheckpoint Therapeutics Presents Cosibelimab Longer-Term Results In Advanced CSCCSeptember 16, 2024 | markets.businessinsider.comCheckpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024September 16, 2024 | globenewswire.comCharlotte Airport Checkpoint C closing Thursday for constructionSeptember 6, 2024 | yahoo.comCheckpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comCLT Airport Checkpoint C closing, new American counters open in next step of expansionSeptember 4, 2024 | yahoo.comCCL Label Debuts Innovative RFID Solutions at Labelexpo 2024 with Checkpoint SystemsAugust 27, 2024 | tmcnet.comEMulate Therapeutics Inc. Announces Publication of Pre-Clinical Mouse Model Demonstrating Direct Evidence of Immune Checkpoint Receptor Knock-Down in a Mouse Glioblastoma ModelAugust 20, 2024 | businesswire.comCheckpoint Therapeutics files secondary offering of up to 5.9M sharesAugust 20, 2024 | msn.comVanguard Group Inc. Acquires 369,586 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)Vanguard Group Inc. grew its holdings in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Free Report) by 67.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 917,894 shares of the comAugust 20, 2024 | marketbeat.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest UpdateCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totalling 4,230,000 shares, a growth of 7.4% from the July 15th total of 3,940,000 shares. Based on an average daily volume of 421,200 shares, the short-interest ratio is presently 10.0 days. Approximately 13.9% of the company's shares are short sold.August 19, 2024 | marketbeat.comBurbank Police to Conduct DUI Checkpoint on SaturdayAugust 16, 2024 | msn.comQ3 2024 Earnings Estimate for Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Issued By HC WainwrightCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Free Report) - HC Wainwright reduced their Q3 2024 earnings per share estimates for Checkpoint Therapeutics in a research note issued on Monday, August 12th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.51)August 15, 2024 | marketbeat.comFortress Biotech, Inc.: Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsAugust 14, 2024 | finanznachrichten.deIndividual investors account for 57% of Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) ownership, while public companies account for 9.8%August 14, 2024 | finance.yahoo.comCheckpoint Therapeutics, Inc: Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate UpdatesAugust 14, 2024 | finanznachrichten.deCheckpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate UpdatesAugust 12, 2024 | globenewswire.comCheckpoint Therapeutics Shares Rise After FDA Accepts Resubmission of CosibelimabJuly 25, 2024 | marketwatch.com Get Checkpoint Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter. Email Address This Indicator called BOTH NVDA rallies (Ad)Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. CKPT Media Mentions By Week CKPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CKPT News Sentiment▼0.680.60▲Average Medical News Sentiment CKPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CKPT Articles This Week▼173▲CKPT Articles Average Week Get Checkpoint Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Stoke Therapeutics News Today CARGO Therapeutics News Today Exscientia News Today ORIC Pharmaceuticals News Today Terns Pharmaceuticals News Today Phathom Pharmaceuticals News Today Tourmaline Bio News Today ProKidney News Today Ginkgo Bioworks News Today Astria Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CKPT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Checkpoint Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CKPT Stock Alerts